Erasca, Inc. ERAS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product candidate is naporafenib, which is currently in pivotal Phase 3 trials (SEACRAFT-2) for patients with NRAS-mutated m…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees103
TickerERAS
Statistics
Market Cap$4.32B
Revenue (TTM)$0
Net Income-$124.5M
Net Margin—
EPS$-0.44
P/E-31.89
P/S—
P/B10.56
EV/EBITDA-30.30
ROE-69.9%
Dividend Yield—
Price$13.90
Data: Twelve Data · Revenue = mcap / P/S